History
|
2016 |
|
The multinational doubleblind and placebo controlled Phase IIb clinical trial for ICEF15 was completed. |
|
2015 |
|
Innovacell completes the single center pharmacodynamic study for ICES13 which was carried out at the Faculty of Medicine of the University of Ljubljana, Slovenia. |
|
2013 |
|
Innovacell and Norgine announce a cooperation and licensing agreement covering ICEF15. This co-operation introduces additional development marketing know-how to the enterprise. |
|
2013 |
|
Innovacell launches a pharmaco-dynamic study for ICES13 in Slovenia, alongside its Phase III study. |
|
2012 |
|
Innovacell successfully concludes the second, single-centre Phase I/II study. |
|
2012 |
|
Ground-breaking findings from the Phase III study of ICES13 allow for a more gentle and simple treatment. |
|
2011
|
|
Innovacell successfully concludes the multi-centre Phase IIb study conducted at 32 centres in four European countries and launches a multi-centre Phase III study in six European countries. |
|
2010 |
|
Innovacell begins the Phase IIb clinical trials for ICES13 in four European countries. |
|
2009 |
|
Innovacell gets approval from the European health authorities to begin the Phase IIb clinical trials of ICES13. Innovacell installs a cryo-preservation unit. This allows cell cultures to be stored over a longer period without any reduction in quality, to the highest safety standards, thus ready to be shipped and implanted at a time of the patient's own choosing. |
|
2008 |
|
Innovacell sets its sights on future expansion and becomes a private limited company in private ownership. The first patients are treated within the framework of clinical trials with cell-therapy product ICEF15. |
|
2007 |
|
The European Patent Office (EPO) grants Innovacell patent protection for Sonoject®, its innovative injection device. More than 500 patients have already been treated with a precursor product of ICES13. The clinical development of ICES13 begins with the entry into force of EU Edict 1394/2007. |
|
2006 |
|
Marketing of cell-therapies begins. |
|
2005 |
|
Innovacell commissions Europe's largest facility for producing autologous cell-therapy treatments. |
|
2002 |
|
The first patients receive treatment within the framework of clinical studies into cell therapy. |
|
2001 |
|
Innovacell wins the Tyrolean business plan competition |
|
2000 |
|
Innovacell Biotechnologie GmbH is founded as a spin-off enterprise of Innsbruck Medical University. |